Cognition Therapeutics, Inc. Profile Avatar - Palmy Investing

Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead…

Biotechnology
US, Purchase [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Cognition Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of CGTX's Analysis
CIK: 1455365 CUSIP: 19243B102 ISIN: US19243B1026 LEI: - UEI: -
Secondary Listings
CGTX has no secondary listings inside our databases.